List view / Grid view
Researchers say their new process enables the synthesis of phenazinones, some of which have high selective toxicity for cancer cells and could be promising anticancer drugs in future.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.
Researchers have prevented immune cells from attacking myelin in mice, which stopped the progression of multiple sclerosis (MS).
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
By blocking the lymphotoxin beta receptor signalling pathway, researchers were able to prevent COPD progression and induce a full restoration of lung tissue.
